Clinical case of successful treatment of Goodpasture syndrome with rituximab

A clinical case of the successful use of rituximab in a patient with severe course of Goodpasture syndrome is described. The patient was admitted to the hospitaal in extremely serious condition with the manifestations of respiratory and renal failure, which required constant respiratory support and...

Full description

Bibliographic Details
Main Authors: I.Yu. Golovach, O.B. Yaremenko, V.P. Stelmashchuk, T.M. Chipko, A.V. Korochev, E.M. Mikhalchenko, L.V. Mikhalskaya
Format: Article
Language:English
Published: Zaslavsky O.Yu. 2018-03-01
Series:Počki
Subjects:
Online Access:http://kidneys.zaslavsky.com.ua/article/view/127401
_version_ 1819105104305848320
author I.Yu. Golovach
O.B. Yaremenko
V.P. Stelmashchuk
T.M. Chipko
A.V. Korochev
E.M. Mikhalchenko
L.V. Mikhalskaya
author_facet I.Yu. Golovach
O.B. Yaremenko
V.P. Stelmashchuk
T.M. Chipko
A.V. Korochev
E.M. Mikhalchenko
L.V. Mikhalskaya
author_sort I.Yu. Golovach
collection DOAJ
description A clinical case of the successful use of rituximab in a patient with severe course of Goodpasture syndrome is described. The patient was admitted to the hospitaal in extremely serious condition with the manifestations of respiratory and renal failure, which required constant respiratory support and hemodialysis. The diagnosis of Goodpasture syndrome was made on the ground of isolated lung and kidney damage as a type of rapidly progressing glomerulonephritis and hemorrhagic alveolitis, high titers of anti-glomerular basement membrane antibo­dies (twice), no increase in the level of other antibodies specific for systemic connective tissue diseases and systemic vasculitis. The patient underwent synchronous pulse therapy with sequential application of cascade plasma filtration, cyclophosphamide and methylprednisolone, without significant improvement. The rationale for the use of rituximab in Goodpasture syndrome was literature data, description of clinical cases, as well as a more than 2-fold increase in CD19+, a high level of anti-glomerular basement membrane antibodies, anemic syndrome and thrombocytopenia, as well as failure of previous immunosuppressive therapy. Therapy with rituximab was performed at a dose of 1000 mg twice with a break of 14 days. A significant improvement in the clinical condition of the patient was noted, as well as restoration of ability to spontaneously breathe, the absence of dyspnoea at rest and on exertion, the absence of hemoptysis, the norma­lization of platelet and hemoglobin indices, the improvement of lung picture on computed tomogram, and a repeated blood test for antibodies to the basal membranes of the glomerular apparatus indicated their absence. Rituximab therapy conducted in the first month after the diagnosis of Goodpasture syndrome contributed to a positive change in the course of the disease, almost complete reversal of lung damage, elimination of life-threate­ning cytopenia and, ultimately, saving of the patient’s life. As in a number of other clinical observations, treatment with ritu­ximab was ineffective in restoring kidney function.
first_indexed 2024-12-22T02:16:56Z
format Article
id doaj.art-5c14469c0a204c999a64421f5b1169fc
institution Directory Open Access Journal
issn 2307-1257
2307-1265
language English
last_indexed 2024-12-22T02:16:56Z
publishDate 2018-03-01
publisher Zaslavsky O.Yu.
record_format Article
series Počki
spelling doaj.art-5c14469c0a204c999a64421f5b1169fc2022-12-21T18:42:16ZengZaslavsky O.Yu.Počki2307-12572307-12652018-03-017213814810.22141/2307-1257.7.2.2018.127401127401Clinical case of successful treatment of Goodpasture syndrome with rituximabI.Yu. Golovach0O.B. Yaremenko1V.P. Stelmashchuk2T.M. Chipko3A.V. Korochev4E.M. Mikhalchenko5L.V. Mikhalskaya6Clinical Hospital “Feofaniya” of the Agency of State Affairs, Kyiv, UkraineBogomolets National Medical University, Kyiv, UkraineClinical Hospital “Feofaniya” of the Agency of State Affairs, Kyiv, UkraineClinical Hospital “Feofaniya” of the Agency of State Affairs, Kyiv, UkraineClinical Hospital “Feofaniya” of the Agency of State Affairs, Kyiv, UkraineClinical Hospital “Feofaniya” of the Agency of State Affairs, Kyiv, UkraineClinical Hospital “Feofaniya” of the Agency of State Affairs, Kyiv, UkraineA clinical case of the successful use of rituximab in a patient with severe course of Goodpasture syndrome is described. The patient was admitted to the hospitaal in extremely serious condition with the manifestations of respiratory and renal failure, which required constant respiratory support and hemodialysis. The diagnosis of Goodpasture syndrome was made on the ground of isolated lung and kidney damage as a type of rapidly progressing glomerulonephritis and hemorrhagic alveolitis, high titers of anti-glomerular basement membrane antibo­dies (twice), no increase in the level of other antibodies specific for systemic connective tissue diseases and systemic vasculitis. The patient underwent synchronous pulse therapy with sequential application of cascade plasma filtration, cyclophosphamide and methylprednisolone, without significant improvement. The rationale for the use of rituximab in Goodpasture syndrome was literature data, description of clinical cases, as well as a more than 2-fold increase in CD19+, a high level of anti-glomerular basement membrane antibodies, anemic syndrome and thrombocytopenia, as well as failure of previous immunosuppressive therapy. Therapy with rituximab was performed at a dose of 1000 mg twice with a break of 14 days. A significant improvement in the clinical condition of the patient was noted, as well as restoration of ability to spontaneously breathe, the absence of dyspnoea at rest and on exertion, the absence of hemoptysis, the norma­lization of platelet and hemoglobin indices, the improvement of lung picture on computed tomogram, and a repeated blood test for antibodies to the basal membranes of the glomerular apparatus indicated their absence. Rituximab therapy conducted in the first month after the diagnosis of Goodpasture syndrome contributed to a positive change in the course of the disease, almost complete reversal of lung damage, elimination of life-threate­ning cytopenia and, ultimately, saving of the patient’s life. As in a number of other clinical observations, treatment with ritu­ximab was ineffective in restoring kidney function.http://kidneys.zaslavsky.com.ua/article/view/127401Goodpasture syndromerespiratory failurerenal insufficiencytreatmentrituximabclinical case
spellingShingle I.Yu. Golovach
O.B. Yaremenko
V.P. Stelmashchuk
T.M. Chipko
A.V. Korochev
E.M. Mikhalchenko
L.V. Mikhalskaya
Clinical case of successful treatment of Goodpasture syndrome with rituximab
Počki
Goodpasture syndrome
respiratory failure
renal insufficiency
treatment
rituximab
clinical case
title Clinical case of successful treatment of Goodpasture syndrome with rituximab
title_full Clinical case of successful treatment of Goodpasture syndrome with rituximab
title_fullStr Clinical case of successful treatment of Goodpasture syndrome with rituximab
title_full_unstemmed Clinical case of successful treatment of Goodpasture syndrome with rituximab
title_short Clinical case of successful treatment of Goodpasture syndrome with rituximab
title_sort clinical case of successful treatment of goodpasture syndrome with rituximab
topic Goodpasture syndrome
respiratory failure
renal insufficiency
treatment
rituximab
clinical case
url http://kidneys.zaslavsky.com.ua/article/view/127401
work_keys_str_mv AT iyugolovach clinicalcaseofsuccessfultreatmentofgoodpasturesyndromewithrituximab
AT obyaremenko clinicalcaseofsuccessfultreatmentofgoodpasturesyndromewithrituximab
AT vpstelmashchuk clinicalcaseofsuccessfultreatmentofgoodpasturesyndromewithrituximab
AT tmchipko clinicalcaseofsuccessfultreatmentofgoodpasturesyndromewithrituximab
AT avkorochev clinicalcaseofsuccessfultreatmentofgoodpasturesyndromewithrituximab
AT emmikhalchenko clinicalcaseofsuccessfultreatmentofgoodpasturesyndromewithrituximab
AT lvmikhalskaya clinicalcaseofsuccessfultreatmentofgoodpasturesyndromewithrituximab